SCHEMBL3756328

SCHEMBL3756328

CC(C)(C)[Si](OCCOc1cccn(-c2ccc([N+](=O)[O-])cc2Cl)c1=O)(c1ccccc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.42
ALDH1A1 P00352 7/20 0.42
SMN1; SMN2 Q16637 6/20 0.42
LMNA P02545 6/20 0.42
HPGD P15428 4/20 0.42
KMT2A Q03164 4/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
CYP1A2 P05177 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MAPK1 P28482 4/20 0.42
HTT P42858 3/20 0.37
GAA P10253 1/20 0.37
MEN1 O00255 3/20 0.35
NR1I2 O75469 1/20 0.34
OPRK1 P41145 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16502415 0.93 MAPT (0.41) MAPTALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL3643585 0.86 CYP3A4 (0.34) MAPTALDH1A1CYP3A4GAA
SCHEMBL2475608 0.84 ALDH1A1 (0.39) MAPTALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL3683302 0.80 MAPT (0.46) MAPTALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL2475752 0.77 MAPT (0.38) MAPTALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL2473621 0.76 NPC1 (0.35) MAPTALDH1A1SMN1; SMN2KMT2ACYP3A4
SCHEMBL3639740 0.76 MAPT (0.61) MAPTALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL2474449 0.75 MAPT (0.39) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL2513578 0.74 F2RL3 (0.36) MAPTALDH1A1LMNAKMT2ARAB9A
SCHEMBL2475859 0.74 NPC1 (0.36) MAPTALDH1A1SMN1; SMN2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
EP-2167499-B1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Pharma AG (DE) 2011-12-14 EP disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, OXA1L, PPOX MAPT 4810/4885ALDH1A1 441/4885SMN1; SMN2 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.